Phase 3 Type 2 Diabetes Trial, Recruiting NCT07060456 Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 3 Type 2 Diabetes Trial, Recruiting

NCT07060456
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able and willing to sign a written consent form
  • People who have been diagnosed with type 2 diabetes for at least 90 days
  • People who have been on a stable, once-daily dose of basal insulin (with or without metformin and/or an SGLT2 inhibitor medication) for at least 90 days
  • People whose HbA1c blood sugar control measure is between 7.5% and 11.0% at the time of screening
  • People with a Body Mass Index (BMI) of 22 or higher at the time of screening

Who may not be able to join:

  • People with a history of type 1 diabetes, or other specific or secondary forms of diabetes
  • People who have had a severe low blood sugar episode in the 180 days before screening
  • People who have had a serious heart or stroke-related event in the 180 days before screening
  • People who have had a cancer diagnosis within the past 5 years
  • People with a known or suspected allergy or sensitivity to the trial medication or related products
  • People who have taken part in another clinical trial within the last 90 days
  • People whom the trial doctor determines may not be suitable to participate for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-0518-82342973

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
25 July 2025
Est. completion
1 February 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change in HbA1c

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov